Previous studies have shown that 100 nM 5-fluoroorotate (5-FO) is sufficient to block the in vitro proliferation of Plasmodium fakciparum without causing toxicity to mammalian cells. In anticipation of potential drug resistance, a study was undertaken to identify P. falciparum cells that would proliferate in the presence of 5-FO. About 3 x 106 UV-irradiated as well as nonirradiated parasites were subjected to a one-step selection with 100 nM 5-FO both in the absence and in the presence of preformed pyrimidines (uracil, uridine, thymine, and thymidine). The P. falciparum cells that emerged after 3 weeks were cloned, and the 90% inhibitory concentration of 5-FO for the cloned cells was found to be 100-to 400-fold greater than that for the parent cell line. Two clones that were further characterized retained resistance to 5-FO even after prolonged propagation in culture without drug pressure. Since the mutants were not cross-resistant to 5-fluorouracil or to dihydrofolate reductase inhibitors, it was unlikely that alteration of thymidylate synthase or overproduction of the bifunctional dihydrofolate reductase-thymidylate synthase was responsible for 5-FO resistance. Similarly, resistance was not due to the expression of a pyrimidine salvage pathway since the cells were not pyrimidine auxotrophs, they did not show increased utilization of pyrimidine nucleosides, and they did not show increased susceptibility to 5-fluoropyrimidine nucleosides. However, the mutant parasites did show as much as a 40-fold lower level of utilization of exogenous radioactive orotate, suggesting that the decreased susceptibility to 5-FO was due to decreased transport or decreased activation of this compound to fluorinated nucleotides. When the selection experiments were repeated, without mutagenesis, in the presence of l0-7 M 5-FO with fewer than 106 parasites or in the presence of more than 10-7 M 5-FO with more than 108 parasites, viable mutants could not be recovered from the cultures. The implications of these findings for the in vivo use of 5-FO for malaria chemotherapy are discussed.
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Malaria continues to be one of the prevalent causes of morbidity and mortality around the world (19) . Inhibitors of de novo pyrimidine metabolism may be suitable as antimalarial agents since the blood-stage forms of Plasmodium spp. lack enzymes that can be used to salvage preformed pyrimidines (29, 30) . In the past it has been demonstrated that a combination of 5-fluoroorotate (5-FO) and uridine allowed for a 1,000-fold difference in the 50% inhibitory concentrations (IC50s) for malarial and mammalian cells in culture (27) . The nanomolar concentrations of 5-FO that caused the inhibition of parasite proliferation also inactivated malarial thymidylate synthase activity and triggered cell death (28, 32) .
It was shown that a combination of 5-FO and uridine was effective not only in vitro but also in vivo; mice infected with a lethal strain of Plasmodium yoelii could be cured with a combination of 5-FO and uridine (12, 26) . However, the concentrations of 5-FO in plasma that were necessary to prevent recrudescence were 100-fold greater than the in vitro concentrations required to inhibit 99% of P. falciparum in culture (26, 27) . Since 5-FO has cytocidal activity against malarial parasites, the recrudescence could not be due to the arrest of parasite proliferation and then normal growth (32) . There remained two possible explanations for the discrepancy between the in vitro effectiveness of 5-FO against P. falciparum and the in vivo effectiveness against P. yoelii. One was that the two species had "intrinsic" variations in their susceptibilities to 5-FO. The other potential explanation was that the mutation frequency for 5-FO is high enough that with a heavy parasite load, as experienced prior to the treatment of mice with 5-FO, a few cells happen to be resistant to 5-FO. Under these conditions plasma 5-FO concentrations that are enough to kill 99.9% of the cells may not be sufficient to kill the genetic variants, and this could give rise to recrudescence. If the latter hypothesis is correct, given a chance, a large enough population of P. falciparum cells in culture should also be able to generate 5-FO-resistant parasites.
The development of 5-FO-resistant P. falciparum was undertaken because it is important to know if the clinically important human malarial parasite can develop resistance to 5-FO and also because the ability of P. falciparum to propagate in culture was expected to facilitate the biochemical and genetic characterization of such mutants.
MATERIALS AND METHODS
Reagents. 5-FO, 5-fluorouracil, 5-fluorouridine, 5-fluoro-2'-deoxyuridine, pyrimethamine, methotrexate, uracil, uridine, thymine, thymidine, and RPMI 1640 culture medium were purchased from Sigma Chemical Co. (St. Louis, Mo.). American Radiolabeled Chemicals (St. Louis, Mo.) supplied [G-3H] hypoxanthine (10 Ci/mmol), [2-14C] orotate (55 xCi/ ,umol), [5-3H] orotate, [6-3H] uracil (10 Ci/mmol), [6-3H] (69 Ci/mmol). Human erythrocytes and plasma were obtained through the American Red Cross (Baltimore, Md.).
Parasites. The experiments described in this report were performed with a subclone of P. falciparum clone W2 from Indochina (20, 27) . Parasites were cultured in vitro as described previously (14, 31) .
Susceptibility of P. falciparum to UV light. In the first stage of the experiment, parasitized cells were concentrated and exposed to UV light for different durations. A 10-ml culture of P. falciparum at 2% hematocrit and 5% parasitemia was centrifuged at 2,000 x g for 5 min. The pellet was washed two times with RPMI 1640 medium without plasma (RPMI wash medium). The cell pellet was resuspended in 1 ml of wash medium. Ten different sterile tissue culture dishes were set up, and each one received 100 ,u of the resuspended parasitized erythrocytes. The contents of six dishes were exposed to UV light in a Germicidal Box (Sylvania G30T8 lamp; Lab Con Co., Kansas City, Mo.); the plates were 45 cm from the source, and exposure times ranged from 5 s to 10 min. Control plates were left in the irradiation chamber with the UV light off for up to 10 min. The contents of each of the sterile dishes were transferred to individual sterile centrifuge tubes in a total volume of 600 RI. The cells were pelleted, the supernatant from each tube was discarded, and the irradiated cells were resuspended in 1 ml of wash medium. At this point the erythrocytes were back to a hematocrit of 2%.
In the second stage, the viabilities of the UV-exposed parasites were tested. From each of the tubes carrying 1 To generate UV-treated cells, a 30-ml culture of P. falciparum at 0.2% hematocrit and 5% parasitemia was centrifuged at 2,000 x g for 5 min. The cell pellet, containing approximately 107 parasitized erythrocytes, was resuspended in 3 ml of wash medium and was UV irradiated for 5 min in a sterile petri dish as described above. The cells were collected in a sterile centrifuge tube and were resuspended in 30 ml of RPMI 1640 medium with 20% human plasma. At this point, the cells were split into two flasks (15 ml each). One flask was labelled "FOR," for 5-FO-resistant parasites, and it received 0.6' ml of 50% erythrocytes and 0.3 ml of 10 jiM 5-FO. The second flask with 15 ml of culture was labelled "FOR-PA," for 5-FOresistant parasites that might be pyrimidine auxotrophs; this flask received 0.6 ml of 50% erythrocytes, 0.3 ml of 10 ,uM 5-FO, and 0.3 ml of concentrated pyrimidine solution (10 mM uridine, 10 mM uracil, 0.1 mM thymidine, and 0.1 mM thymine). Finally, a third flask containing 30 ml of parasites (0.2% hematocrit and 7% parasitemia) was treated with 5-FO without UV irradiation; this flask was labelled "NR-FOR" for natural resistance to 5-FO.
For propagating 5-FO-resistant parasites, the medium in each of the flasks described above was changed once every 48 h with 0.1 ,uM 5-FO in the culture medium. Pyrimidines were included in the culture medium for flask FOR-PA. On days 7, 13, and 20, the cultures were split 1:2 with culture medium containing fresh erythrocytes. On these days, a small portion of the culture material was smeared onto a slide and the slide was stained with Giemsa in order to observe the appearance of parasites. Parasites were first seen on day 20; flask FOR had 2.7% parasitemia, flask FOR-PA had 4% parasitemia, and flask NR-FOR had 2.9% parasitemia. The parasites were cultured in 40 ml of medium with 5-FO at 2% hematocrit. Over the next 2 weeks parasites were split 1:4 whenever they reached a density of 4 to 6% parasitemia. During these splits, 30 ml of culture was used for cryopreservation and 10 ml was diluted 1:4 with fresh 2% erythrocytes. Cloning of 5-FO-resistant parasites. Parasites from flasks FOR, FOR-PA, and NR-FOR were diluted into 96-well plates at a density of 0.5 parasites per well (32) . The parasites in these wells, which contained 200 ,lI of medium with 2% hematocrit, were propagated as described previously (32) . After 2 weeks the contents of the 96-well plates were replica plated into another set of 96-well plates. Wells were considered positive for parasites if they accumulated hypoxanthine in precipitable material (8, 32) . On the basis of this the contents of the appropriate well from the replica plate were transferred into 10-ml culture flasks.
Susceptibilities of mutants to antimetabolites. 5-FO, a series of related 5-fluoropyrimidine antimetabolites, and structurally unrelated inhibitors of malarial parasites, were tested for antimalarial activity by in vitro antiproliferation assays (8) . Parasite-infected erythrocytes (0.5% parasitemia, 2% hematocrit) in 96-well plates were exposed to the antimetabolites for 48 h and then to radioactive hypoxanthine for a 24-h exposure. The amount of radioactivity in the precipitable material served as an index of cell proliferation. For each of the different antimetabolites, the susceptibilities of parental W2 clones were compared with those of 5-FO-resistant mutants.
Metabolic patterns of mutant parasites. Two approaches were used to test for alterations in pyrimidine metabolism in 5-FO-resistant parasites.
In the first approach, the abilities of cloned 5-FO-resistant parasites to utilize different radiolabeled pyrimidines were compared with that of the parent isolate (W2). Clone D8 from the FOR flask was used, and clone H9 from the FOR-PA flask was used. The parasites were set up in a culture volume (Fig. 1) . After a 5-min exposure, the proliferation rate was about half of that of nontreated cells. Control populations kept in the UV box without irradiation did not show decreased levels of proliferation (data not shown).
Selection of P. fakiparum resistant to 5-FO. Populations of parasites that had been exposed to UV light for 5 min were exposed to 5-FO in the absence of exogenous pyrimidines (flask FOR) or in the presence of pyrimidines (flask FOR-PA; 100 ,uM uridine, 100 ,uM uracil, 1 ,uM thymidine, and 1 ,uM thymine). A third population of parasites was exposed to 5-FO without prior UV treatment (NR-FOR). Two weeks after continuous exposure of 3 x 106 infected erythrocytes per flask to 100 nM 5-FO, no parasites were visible. However, after 3 weeks all flasks showed viable parasites (Fig. 2) . Interestingly, the rate of appearance of 5-FO-resistant parasites did not depend on whether they had been treated with UV light. Similarly, the appearance of 5-FO resistance was not faster in flasks that had pyrimidines.
To determine the concentration range within which mutants could be obtained in a one-step selection protocol and to get an estimate of the mutation frequency for 5-FO resistance in P. falciparum, selection was repeated in two ways. In one experiment, in the absence of mutagenesis, 108 parasites per flask were exposed to various amount of 5-FO. All flasks containing 10-7 M 5-FO showed parasites in about 25 days. However, parasites did not emerge from flasks treated with 10-6 or 10-5 M 5-FO. In a second experiment, parasite cultures containing various number of parasites per flask were exposed to a fixed inhibitors of dihydrofolate reductase. In order to determine if the 5-FO-resistant isolates showed cross-resistance to metabolically related inhibitors, the susceptibility patterns of clones W2, FOR/D8, and FOR-PA/H9 were compared (Table 1) .
While clones FOR/D8 and FOR-PA/H9 were about 100 times more resistant to 5-FO, they did not show comparable levels of resistance to other 5-fluoropyrimidines (5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine). The susceptibilities of the mutant cell lines to pyrimethamine and methotrexate also remained essentially unaltered ( Table 1) .
Utilization of exogenous pyrimidines. In order to determine if the mutant parasites had altered patterns of pyrimidine metabolism, clones W2, FORID8, and FOR-PA/H9 were exposed to exogenous radioactive precursors of pyrimidine nucleotides. After 24 h the amount of radioactivity taken up and incorporated into parasite nucleic acids was measured ( Table 2 ). The utilization of orotic acid was sharply decreased in 5-FO-resistant parasites. When [2-'4C]orotate was used, there was a 13-to 40-fold decrease in the labelling of nucleic acids after correction for variations in hypoxanthine uptake. With [5-3H] orotate, the decrease was 6-to 12-fold. Most likely, this difference was due to the higher specific activity and lower molar levels of orotate in the medium when tritium was used. The uptake of uracil, uridine, deoxyuridine, thymine, and thymidine by all strains was close to zero. Any apparent differences in the utilization of these latter compounds by the three clones were statistically insignificant.
DISCUSSION
In this report it is shown that human malarial parasites in culture can readily develop 100-fold resistance to 5-FO. This finding was not totally unexpected since the introduction of every antimetabolite against malarial parasites has been followed by the appearance of drug-resistant strains in a very short time (21) . Resistance to cycloguanil was found in the laboratory and in the field within a year after the compound was introduced as therapy, and resistance to pyrimethamine was seen in the laboratory prior to introduction of the drug as therapy (15, 21) . An understanding of the mechanism of resistance to a new agent and an appreciation of the ease with which parasites can develop resistance to it are essential for the judicious use of the compound.
In light of recent evidence that the antimalarial activity of 5-FO probably involves inactivation of malarial thymidylate synthase (28) , one would have expected resistance to occur through several potential mechanisms. However, in all cases examined, the only significant metabolic difference between 5-FO-susceptible and 5-FO-resistant parasites was in their ability to utilize exogenous radioactive orotic acid. This suggested that the parasites had altered means of transport of orotate and 5-FO or altered levels of activation of these compounds to orotidylic acid and 5-fluoroorotidylic acid, respectively. In principle, alterations in thymidylate synthase structure or overproduction of thymidylate synthase could have resulted in resistance to 5-FO. However, such a mechanism of resistance would also provide cross-resistance to related compounds such as 5-fluorouracil. This was not seen with the mutants found in the present study. Since malarial parasites express thymidylate synthase as part of a bifunctional protein with dihydrofolate reductase (3, 4, 11) , overexpression of the complete protein would also have resulted in crossresistance to dihydrofolate reductase inhibitors such as pyrimethamine and methotrexate. Such cross-resistance was also not seen in the present study. Finally, even though the erythrocytic stages of malarial parasites lack the enzymes for the salvage of preformed pyrimidines (29, 30) (2, 5, 6, 9, 13, 18) . One characteristic of such resistance is that, in the absence of drug pressure, the parasites readily loose the self-replicating extrachromosomal DNA and the associated drug resistance phenotype. There is no precedence for this type of resistance in plasmodia, and the characteristics of 5-FO resistance in P. falciparum also indicate a stable resistance phenotype like the kind observed for pyrimethamine and cycloguanil resistance in malaria parasites (7, (22) (23) (24) 33 ) and a variety of transport mutants in other parasites (10, 16, 17, 25) .
A particularly noteworthy result of the present study was that, once the appropriate selection conditions had been optimized, it was relatively easy to obtain 5-FO-resistant parasites. Starting with 5 x 106 parasitized erythrocytes per flask, 5-FO-resistant parasites could be seen within 3 weeks. This was true regardless of whether the parasites had been mutagenized (with UV light) or not and regardless of whether the parasite had been presented with opportunities to develop other types of drug resistance (see discussion above). It is estimated that the forward mutation frequency for 5-FO resistance is about 10-6. The alternative mechanisms for drug resistance discussed above may occur less frequently, and parasites with those mutations were probably "masked" by the types that were commonly observed in this study. For the purpose of comparison, it should be noted that Banyal and Inselburg (1) were able to select for pyrimethamine resistance from 5 x 10 nonmutagenized parasites, although the selection was not carried out in a single step.
The present in vitro study has significant implications for the potential in vivo use of 5-FO for malaria chemotherapy. In experimental models, a mouse displaying 5 to 10% parasitemia may have anywhere from 109 to 1010 parasites (15) . If the mutation frequency for 5-FO resistance in P. yoelii is similar to that for P. falciparum (about 10-6), it would not be surprising to see recrudescence if serum 5-FO levels remain less than 1 ,uM. Indeed, when 5-FO was used as single agent, the levels of 100 nM in serum were not sufficient to avoid recrudescence (12) . It was necessary to raise the 5-FO levels in plasma to as high as 10 ,uM to avoid recrudescence (12) . Perhaps not coincidentally, in the present study, when P. falciparum cells in culture were exposed to concentrations of 1 to 10 ,uM 5 
